# A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

> **NCT02936102** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 154 (actual)

## Conditions studied

- Advanced Solid Tumors
- Triple Negative Breast Cancer
- Chordoma and Alveolar Soft Part Sarcoma

## Interventions

- **DRUG:** FAZ053
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02936102
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-20
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 154 (ACTUAL)
- **Why stopped:** The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936102, "A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02936102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*